XORTX Therapeutics Inc (XRTX) AI Stock Analysis

• Market Cap: C$4.46M
• Dividend Yield: N/A
• Average Volume (3M): 11.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: N/A
• EPS Growth: -1939.32%
• Country: CA
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 6,962,218
• 10 Day Avg. Volume: 30,736
• 30 Day Avg. Volume: 11,079
• PEG Ratio: 0.02
• Price to Book (P/B): 1.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.61 ▼(-21.28% Downside)
• Action: Reiterated Date: 03/01/26
• Date: Action: Reiterated 03/01/26

The score is driven primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn despite some improvement) and bearish technicals (below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend.

Positive Factors

Low leverage / Minimal debt

Minimal debt reduces solvency risk and preserves strategic optionality for a development-stage biotech. With little leverage the company can prioritize financing clinical programs and avoid near-term interest burdens, a durable strength if cash planning is prudent.

Improving cash burn trend

A multi-year reduction in cash outflows indicates improving operational discipline and lower incremental funding needs. Sustained moderation in burn rate extends runway and reduces dilution risk relative to prior years, a structural improvement for funding clinical development.

Focused clinical-stage pipeline

A clear, concentrated pipeline targeting chronic kidney disease and ADPKD creates focused R&D priorities and potential regulatory clarity. Specialization around oxypurinol can yield deeper expertise and efficient resource allocation, a durable competitive setup if clinical results progress.

Negative Factors

No revenue / persistent losses

Absence of revenue and ongoing operating losses mean the company cannot self-fund operations and must rely on external capital or partnerships. This structural lack of internal cash generation increases execution risk for multi-year clinical programs.

Continued cash burn / financing need

Persistent negative operating and free cash flow creates a recurring need to raise capital or secure partners. Repeated financings can dilute shareholders, constrain strategic choices, and create dependence on market conditions—an enduring risk until commercial revenues appear.

Eroded equity base

A materially reduced equity cushion limits the firm's ability to absorb adverse outcomes and makes non-dilutive financing harder to obtain. Continued erosion of net assets signals capital strain and raises the probability that future funding will be costly or dilutive.

XORTX Therapeutics Inc Business Overview & Revenue Model

Company Description

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

How the Company Makes Money

null

XORTX Therapeutics Inc Financial Statement Overview

Summary

Financials reflect an early-stage biotech with no revenue, ongoing operating/net losses, and continued negative operating and free cash flow. Losses and cash burn have moderated versus 2022, and leverage is minimal, but the sharp erosion in equity and lack of self-funding keep overall financial strength weak.

Income Statement

The income statement remains very weak: the company reports no revenue across the period provided and continues to generate operating losses and net losses. Losses have narrowed versus 2022 (net loss improved from about -$12.4M at the operating level in 2022 to about -$4.5M in 2025), but profitability is still firmly negative and the business has not yet demonstrated a revenue base to absorb costs.

Balance Sheet

Leverage is low, with debt staying minimal (debt-to-equity roughly ~0.0–0.02), which reduces solvency risk. However, the equity base has declined materially (from ~$13.2M in 2021 to ~$2.9M in 2025) and returns on equity are deeply negative, reflecting ongoing losses and balance sheet erosion.

Cash Flow

Cash burn remains significant, with operating cash flow and free cash flow negative each year. A positive sign is that cash outflows have generally moderated from 2022–2023 to 2024–2025 (free cash flow improving from roughly -$9.0M in 2022 to about -$3.9M in 2025), but the company is still not self-funding and will likely depend on external financing until revenues or meaningful cost reductions emerge.

Breakdown	Dec 2025	Dec 2024	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-156.66K	-160.66K	―	-75.27K	-17.88K
EBITDA	-4.39M	-4.38M	―	-9.41M	―
Net Income	-3.71M	-4.54M	―	―	-1.65M
Balance Sheet
Total Assets	3.68M	5.89M	5.47M	12.37M	17.38M
Cash, Cash Equivalents and Short-Term Investments	1.19M	3.56M	3.45M	10.43M	14.79M
Total Debt	51.11K	55.78K	11.51K	77.60K	0.00
Total Liabilities	821.18K	1.09M	825.94K	5.38M	4.18M
Stockholders Equity	2.86M	4.80M	4.64M	7.00M	13.20M
Cash Flow
Free Cash Flow	-3.87M	-5.04M	-6.63M	-9.01M	-4.83M
Operating Cash Flow	-3.87M	-5.04M	-6.58M	-8.96M	-4.80M
Investing Cash Flow	-412.13K	-53.32K	-46.36K	-45.70K	-31.81K
Financing Cash Flow	1.99M	3.81M	-487.30K	4.71M	19.37M

XORTX Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.78
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:XRTX, the sentiment is Neutral. The current price of 0.78 is above the 20-day moving average (MA) of 0.56, above the 50-day MA of 0.63, and below the 200-day MA of 0.95, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.92 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:XRTX.

XORTX Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APS	51 Neutral	C$5.69M	-0.15	123.88%	―	―	90.81%
MOOD	45 Neutral	C$5.61M	-4.13	-41.36%	―	-50.89%	-32.33%
XRTX	42 Neutral	C$4.46M	-0.98	-111.11%	―	―	-1939.32%
KNE	41 Neutral	C$5.46M	-3.10	―	―	―	―
BIOV	29 Underperform	C$2.33M	-1.60	―	―	―	25.09%

XORTX Therapeutics Inc Corporate Events

XORTX Reshapes Board to Meet Conditions for Planned Financing

XORTX Therapeutics Inc. plans to nominate three new directors, George Scorsis, Richard Grieve, and Mika Grasso, at its March 24, 2026 annual and special shareholder meeting, replacing three previously proposed nominees. The board changes are a condition of a significant financing initiative currently under negotiation, which, if not completed, will see the new directors resign and their seats refilled later, with the financing also requiring TSX Venture Exchange approval.

The proposed directors bring experience in highly regulated industries, finance, operations, and investment management, notably including Scorsis’s track record scaling consumer and cannabis businesses and executing major M&A and financing transactions. Their addition is intended to support XORTX’s capital-raising efforts and may strengthen governance and strategic execution as the company advances its late-stage pharmaceutical programs.

The most recent analyst rating on (TSE:XRTX) stock is a Sell with a C$0.48 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.

Proxy Advisers Back XORTX Share Consolidation Plan Ahead of March Vote

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, develops therapies for gout and progressive kidney disease, including advanced programs XRx-026, XRx-008 and XRx-101, plus a pre-clinical candidate for Type 2 diabetic nephropathy. The firm’s drugs target purine metabolism and xanthine oxidase to lower uric acid and address serious renal and metabolic disorders.

The company reported that independent proxy advisory firms, including Institutional Shareholder Services, have recommended shareholders vote in favor of a proposed share consolidation at its March 24, 2026 meeting. The endorsement is seen as supporting XORTX’s view that consolidation could broaden financing alternatives and bolster long-term growth prospects, and the board is urging eligible shareholders of record to vote for all resolutions ahead of the March 20 proxy deadline.

The most recent analyst rating on (TSE:XRTX) stock is a Sell with a C$0.61 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.

XORTX Sets March 24 Shareholder Meeting, Puts Share Consolidation to a Vote

XORTX Therapeutics has filed and mailed the management information circular and related materials for its annual and special shareholder meeting, scheduled for March 24, 2026, in Calgary. Shareholders of record as of February 20, 2026, can access the documents online and are urged to vote ahead of the March 20 proxy deadline.

At the meeting, investors will vote on routine corporate matters including setting the board size, electing directors, appointing the auditor, and approving the stock option plan. They will also consider a share consolidation of up to five existing common shares into one, a move that could position the company to better manage its capital structure and potentially support its listings and financing flexibility.

The board unanimously recommends voting in favor of all proposed items and has engaged Laurel Hill Advisory Group to assist shareholders with the voting process. The outcomes of these resolutions, particularly the potential share consolidation, may influence XORTX’s market profile and its ability to fund continued development of its late-stage kidney and gout treatment programs.

The most recent analyst rating on (TSE:XRTX) stock is a Sell with a C$0.46 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.

XORTX Leans Into Genetic Breakthroughs in Gout as It Reshapes Board and Advances Oxypurinol

XORTX Therapeutics highlighted newly published, large-scale genetic research showing that hundreds of genetic factors are implicated in urate biology and gout, reinforcing the central role of xanthine oxidase over-expression in hyperuricemia, gout, polycystic kidney disease and related kidney and metabolic conditions. Management framed these findings as validation of its XO-inhibition strategy and precision medicine focus, noting that its planned clinical trial of oxypurinol is a key step toward a future new drug application and could strengthen the company’s positioning in treating both diabetic and non-diabetic kidney diseases. In a corporate update, XORTX announced the appointment of veteran biotech strategist Krysta Davies Foss to its board and the resignation of three directors, moves that streamline the board and add commercialization and market-preparedness expertise as the company advances its clinical and partnering agenda.

The most recent analyst rating on (TSE:XRTX) stock is a Hold with a C$0.81 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.